All In Biotech

Drug Trial Radar · NCT03033745

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency

Last checked: Nov 19, 2026Latest source record: Mar 25, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

49

Actual

Start

Feb 1, 2017

Primary completion

Dec 14, 2018

Study completion Dec 14, 2018

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Jan 27, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, open-label, parallel-arm, non-randomized study is designed to evaluate safety and tolerability of higher infusion parameters of IgPro20 in subjects with primary immunodeficiency (PID). A total of 45 subjects (including at least 14 \[30%\] pediatric subjects ≤ 17 years of age and at least 9 \[20%\] obese subjects with body mass index \[BMI\] of ≥30 kg/m2) with confirmed PID will be evaluated in the study. The study will include three cohorts of 15 subjects each as follows: i) Pump-Assisted Volume Cohort (weekly infusions), volume per injection site of 25 mL up to 50 mL, ii) Pump Assisted Flow Rate Cohort (weekly infusions), flow rate per injection site of 25 mL/hour up to 100 mL/hour, iii) Manual Push Flow Rate Cohort (2 to 7 infusions per week), flow rate per injection site of 25 to 30 mL/hour up to 120 mL/hour (equivalent of approximately 0.5 mL/minute up to 2 mL/minute). Each cohort will test 3 infusion parameter levels (4 for the pump-assisted flow rate cohort), repeated at least 4 times over a duration of 12 weeks (16 weeks for the flow rate cohort). After 4 infusion weeks at each level, qualifying subjects (responders) will switch to the next infusion parameter level (eg, from 25 to 50 mL/h). During the study, the weekly dose will remain unchanged (as prescribed by treating physician, usually within 100-200 mg/kg per week range); only the respective infusion parameter under evaluation will change.

Conditions

  • Primary Immunodeficiency

Interventions

  • IgPro20Drug

    A liquid formulation of normal human IgG at a concentration of 20% administered as a subcutaneous infusion at a dose prescribed by subject's physician prior to study entry.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of RespondersTime frame: At the end of 4 weeks for each planned infusion parameter

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • Clinical Research Center of Alabama

    Birmingham, Alabama

  • Research Solutions of Arizona

    Litchfield Park, Arizona

  • University of Southern Florida

    St. Petersburg, Florida

  • Georgia Pollens Clinical Research Centers

    Albany, Georgia

  • Long Island Jewish Medical Center

    Great Neck, New York

  • Icahn Medical Institute

    New York, New York

  • Center for Clinical Research Rochester General Hospital

    Rochester, New York

  • Levine Children's Hospital

    Charlotte, North Carolina

  • Duke University School of Medicine

    Durham, North Carolina

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • The Ottawa Hospital

    Ottawa, Ontario, Canada

  • McGill University

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.